From the 1Department of Pediatrics, All India Institute of Medical Sciences (AIIMS), New Delhi, India; 2Department of Pediatrics, Advanced Pediatrics Centre (APC), Post-Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India; and 3Department of Pharmacology, Post-Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
World Allergy Organ J. 2010 Sep;3(9):239-44. doi: 10.1097/WOX.0b013e3181f234d4.
Many randomized controlled trials (RCTs) have been done on role of probiotics as a treatment modality in allergic rhinitis. We conducted a review on the same. A systematic search of published literature was done. RCTs comparing effect of probiotics with placebo were included. A predefined set of outcome measures were assessed. Continuous data were expressed as pooled standardized mean difference (SMD) with 95% confidence interval (CI). Dichotomous data were expressed as odds ratio with 95% CI. P value <0.05 was considered significant. RevMan version 5 was used for all the analyses. Seven RCTs were eligible for inclusion. Probiotic intake improved quality of life score in patients with allergic rhinitis [SMD -1.17 (95% CI -1.47, -0.86; P < 0.00001)]. Other parameter that improved with probiotic intake was decrease in the number of episodes of rhinitis per year. There was no significant change in blood or immunologic parameters in the probiotic group, SMD -0.10 (95% CI -0.26, 0.06; P = 0.22). Adverse events were not significant. Probiotic therapy might be useful in rhinitis, but the present data do not allow any treatment recommendations.
许多随机对照试验(RCT)已经研究了益生菌作为变应性鼻炎治疗方法的作用。我们对此进行了综述。对已发表的文献进行了系统搜索。纳入了比较益生菌与安慰剂疗效的 RCT。评估了一套预设的结局指标。连续数据表示为合并标准化均数差(SMD)及其 95%置信区间(CI)。二分类数据表示为比值比及其 95%CI。P 值<0.05 被认为有统计学意义。所有分析均使用 RevMan 版本 5 进行。有 7 项 RCT 符合纳入标准。益生菌摄入可改善变应性鼻炎患者的生活质量评分[SMD -1.17(95%CI -1.47,-0.86;P < 0.00001)]。益生菌摄入可改善的另一个参数是每年鼻炎发作次数减少。益生菌组的血液或免疫参数无显著变化,SMD -0.10(95%CI -0.26,0.06;P = 0.22)。不良事件不显著。益生菌治疗可能对鼻炎有用,但目前的数据不允许任何治疗建议。